glp 1/gip receptor agonist Dual GIP/GLP-1 agonists: New advances for treating type-2 diabetes Dual GLP-1/GIP Agonist | Tirzepatide

Description

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

People rush to the gym as soon as the new year starts to start prepping for the perfect body for summer

Tirzepatide, the first dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RA approved for both conditions, has paved the ...

Pfizer plans to conduct dose optimization studies in the second half of 2024 evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies

(WROC) Excellus BlueCross BlueShield is pushing back against reports that it will no longer cover GLP-1 medications, saying drugs used to treat certain medical conditions remain cove...